What are the considerations for using tirzepatide (a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist) in patients with pre-existing gastrointestinal conditions, such as gastroparesis, inflammatory bowel disease, or irritable bowel syndrome?
Ask what kind of monitoring is included, how side effects are handled, how often progress is reviewed, and what happens if your body responds more slowly than expected
Daily activity and step tracking to set goals and encourage a healthier lifestyle
Minimizing Risk of Infection Infectious diseases are more frequent and more serious in patients with diabetes mellitus due to the hyperglycemic environment that favors immune dysfunction (e.g., damage to the neutrophil function, depression of the antioxidant system, and humoral immunity), micro-and macro-angiopathies, neuropathy, decrease in the antibacterial activity of urine, gastrointestinal and urinary dysmotility, and the greater number of medical interventions in these patients
